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Tuberculosis (TB) remains one of the leading causes of mortality worldwide, and a lack of
understanding of basic disease pathogenesis is hampering development of new vaccines
and treatments. Multiple studies have previously established a role for type I interferon
(IFN) in TB disease. Type I IFNs are critical immune mediators for host responses
to viral infection, yet their specific influence in bacterial infection remains unclear. As
IFN-stimulated genes (ISGs) can have both stimulatory and inhibitory effects on immune
function, clarifying the role of type I interferon in TB remains an important question.
The quantification of interferon proteins in the circulation of patients has been restricted
until the recent development of digital ELISA. To test the hypothesis that patients with
active TB disease have elevated circulating type I IFN we quantified plasma IFNα and
β proteins with Simoa digital ELISA in patients with active disease and asymptomatic
M. tuberculosis infection. Strikingly no differences were observed between these two
groups, while plasma from acute influenza infection revealed significantly higher plasma
levels of both IFNα and IFNβ proteins. These results suggest a discordance between ISG
mRNA expression by blood leukocytes and circulating type I IFN in TB.
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INTRODUCTION
Blood transcriptional signatures highly enriched for interferon (IFN)-stimulated genes (ISGs) are
a hallmark of tuberculosis (TB) (Moreira-Teixeira et al., 2018), the leading cause of mortality
from an infectious disease. Elevated expression of ISGs in blood leukocytes from patients with
active TB disease has facilitated development of promising blood-based biomarkers that have
diagnostic value for discrimination between individuals with TB disease and asymptomatic
controls (Berry et al., 2010; Maertzdorf et al., 2011; Bloom et al., 2013; Kaforou et al., 2013;
Zak et al., 2016). Consistent with this, we recently published an 11-gene blood signature
primarily comprised of ISGs and showed that signature scores were consistently higher in
TB cases than in controls with asymptomatic (latent) Mycobacterium tuberculosis (M.tb)
infection (LTBI) (Darboe et al., 2018). These data, as well as studies of the immunobiology
of TB suggest that type I and/or II IFNs trigger ISG expression in blood leukocytes,
as observed in viral infections and a number of interferonopathies (McNab et al., 2015).
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Infection with M.tb is known to induce IFNγ-expressing T
cell responses, which are necessary for immunological control
of the bacterium to prevent disease progression (O’Garra
et al., 2013), but it is currently not known if TB disease
is associated with an elevated abundance of IFNα or IFNβ
protein in peripheral blood. Although one study has previously
reported no differences in circulating IFNα2 protein levels in
TB disease (Berry et al., 2010), this conclusion relied on results
from Luminex assays of which the majority of reported values
were at the lower limit of detection of the assay, which we
now know is insufficient for measuring physiological ranges of
IFNα (Rodero et al., 2017).
We hypothesized that patients with active TB had elevated
plasma levels of IFNα or β protein, as observed in respiratory
viral infections. This hypothesis has not been previously tested as
classical ELISAs lack the sensitivity required for reliable detection
of IFNα or β in circulation. However, we recently utilized
digital ELISA technology, based on counting individual enzyme-
labeled immunocomplexes of proteins captured on paramagnetic
beads in single-molecule arrays (Simoa), combined with unique
high-affinity antibodies isolated from APS1/APECED mutation
patients (Meyer et al., 2016) to detect plasma IFNα attomolar
concentrations in viral infections, auto-immune disease, and
interferonopathies (Rodero et al., 2017). Herein, we extended this
approach to also measure IFNβ by digital ELISA, and using these
novel assays we tested the hypothesis that type I IFN proteins are
elevated in the blood during TB disease.
METHODS
Patient Cohorts
Thirty patients (Active TB) with Xpert MTB/RIF (Cepheid)
sputum-positive TB disease (HIV negative) and 30
QuantiFERON (QFT) Gold In-tube (Qiagen) positive
asymptomatic adult controls (LTBI) were recruited from
theWestern Cape Province of South Africa, where TB is endemic
(Table 1). Study participants provided written informed consent
and the study protocol was reviewed and approved by the Human
Research Ethics Committee of the University of Cape Town. As
additional positive and negative controls for type I interferon
responses we also included a cohort of French pediatric patients
(11) with confirmed respiratory influenza viral infection and
healthy donors (n = 30) from Paris (Table 1). Healthy donors
(CoSImmGEn cohort of the Investigation Clinique et Accès aux
Ressources Biologiques (ICAReB) platform, Center de Recherche
Translationnelle, Institut Pasteur, Paris, France) and patients
gave informed consent.
Type I Interferon Assays
IFNα and IFNβ protein plasma concentrations were quantified
by Simoa assays developed with Quanterix Homebrew kits as
previously described (Rodero et al., 2017). For the IFNα assay,
the 8H1 antibody clone was used as a capture antibody after
coating on paramagnetic beads (0.3 mg/mL), the 12H5 clone
was biotinylated (biotin/antibody ratio = 30/1) and used as
the detector, and recombinant IFNα17 (Peprotech) used as the
standard. For the IFNβ assay, the 710322-9 IgG1, kappa, mouse
TABLE 1 | Patient cohort characteristics.
Subject type Country Numbers Age
(Median/range)
Sex
(F/M)
Healthy controls France 30 46/24–67 6/24
Respiratory viral
Infection
France 11 4/1–11 NA
Latent TB (LTBI) South Africa 30 40.5/22–65 22/8
Active TB South Africa 30 34/18–62 8/22
monoclonal antibody (PBL Assay Science) was used as a capture
antibody after coating paramagnetic beads (0.3 mg/mL), the
710323-9 IgG1, kappa, mouse monoclonal antibody (PBL Assay
Science) was biotinylated (biotin/antibody ratio = 40/1) and
used as the detector antibody, and recombinant protein (PBL
Assay Science) were used to quantify IFNβ concentrations. The
limit of detection (LOD) of the IFNα and IFNβ assays were 0.5
fg/mL and 0.2 pg/mL, respectively. Functional activities of type
I IFN were measured using an in vitro cytopathic assay that
has been previously described (Lebon et al., 1979). Briefly IFN
activity was determined by addition of patient plasma to Madin–
Darby bovine kidney (MDBK) cells which were challenged
with vesicular stomatitis virus to measure the viral cytopathic
effect as compared with an IFN standard (Lebon et al., 1979).
Blood ISGs were measured by an 11-gene blood signature score
(ACS TB risk signature) by qRT-PCR from RNA isolated from
PAXgene collected whole blood, as previously described (7). The
raw data (Dataset_1) from the paper is available at Figshare,
doi: 10.6084/m9.figshare.8799131.
Statistical Analysis
For multi-group comparisons, Kruskal-Wallis with Dunn’s
multiple comparison tests were performed (Figures 1A–C). For
two-group comparisons, the Mann-Whitney U test was used
(Figure 1D). Results are graphed on log scales due to the wide
distributions of the data.
RESULTS
Plasma levels of IFNα were detectable in half of the TB patients
and LTBI controls from South Africa, at levels below 100 fg/mL,
but were not different between these two groups (Figure 1A).
Although these South African donors had significantly (p< 0.01)
higher plasma levels of IFNα protein (median 1–2 fg/mL)
than healthy European controls, IFNα levels in individuals
with influenza viral infection were orders of magnitude higher
than individuals in the other three groups with a median
concentration of 39 pg/mL (Figure 1A). Plasma levels of IFNβ,
also measured by digital ELISA but with a commercially sourced
antibody that gives lower sensitivity than the IFNα assay,
were mostly undetectable. However, IFNβ was detected in
all individuals with viral infection at a median concentration
of 5 pg/mL, but was only detected in one TB patient and
two LTBI controls from South Africa (Figure 1B). To further
assess for potential type I interferons not detected by our
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FIGURE 1 | Type I IFN in active TB. (A) IFNα (fg/mL) and (B) IFNβ (pg/mL) concentrations and (C) IFN activity (IU/mL) in plasma from healthy controls (n = 30),
influenza viral infection (n = 11), LTBI (n = 30) and active TB patients (n = 30). (D) ISG score as defined by an 11-gene signature (Darboe et al., 2018) in blood cells
from LTBI (n = 30) and active TB patients (n = 30). (A–C: Kruskal-Wallis with Dunn’s multiple comparison tests were performed; (D) Mann-Whitney U-test). (Digital
ELISA limit of detection is indicated by the dotted line). (E) Spearman correlation between ISG score and plasma IFNα concentrations.
Simoa assays, we tested for functional activities of type I IFN
using an in vitro cytopathic assay that is less sensitive than
the digital ELISA (Lebon et al., 1979). IFN activity in these
plasma samples mirrored the observed protein level results; only
individuals with viral infections had measurable bioactive type
I IFN (Figure 1C). Finally, as shown previously and published
by ourselves and others (Berry et al., 2010; Maertzdorf et al.,
2011; Bloom et al., 2013; Kaforou et al., 2013; Zak et al.,
2016; Darboe et al., 2018), active TB patients had significantly
elevated 11-gene blood signature scores, based on ISG gene
expression, as compared to LTBI (p < 0.0001; Figure 1D) (7).
This ISG gene signature showed no correlation with plasma IFNα
levels (Spearman correlation (95% CI) = 0.06 (−0.21 to 0.32),
p= 0.68; Figure 1E).
DISCUSSION
Our data suggests a discordance between ISG mRNA expression
by blood leukocytes and circulating type I IFN in TB, and reveals
current limitations in our understanding of the immunobiology
of M.tb infection. This capacity to directly measure type I
IFN protein with unprecedented sensitivity can provide novel
insights into the nature, regulation and consequences of the
IFN response in TB disease. The virtual absence of IFNα and
IFNβ in plasma suggests that type I IFN receptor (IFNAR)
triggering in circulating immune cells to activate ISG expression
must be happening in a different compartment, likely at the
site of infection or in draining lymphoid tissues. Why this
is different for TB as opposed to influenza viral infection,
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which revealed highly elevated IFN protein concentrations and
previously described blood ISG signatures (Dunning et al.,
2018), remains unclear. Alternatively, ISG expression may also
be driven by IFNγ, which is well-recognized to be expressed
by M.tb-specific T cells, unconventional T cells and natural
killer cells during M.tb infection and TB disease (O’Garra et al.,
2013). However, plasma levels of IFNγ and the abundance of
IFNγ-expressing T cells do not allow discrimination between
asymptomatic M.tb infection and TB disease (Pai, 2010), and
therefore peripheral blood measures of type II IFN also cannot
explain ISG mRNA expression by blood leukocytes. Since
respiratory viral infections, such as influenza, are associated with
high ISG mRNA expression (Dunning et al., 2018) and thus
can lead to false positive transcriptomic TB signature results
(Singhania et al., 2018), measuring type I IFN proteins could
be used to differentiate between respiratory viral infections and
TB. South African donors, latently infected with M.tb (defined
based on a positive QFT response) were used as the most relevant
control group to compare with active TB disease, and a healthy
European population was also included. While it would have
been interesting to also include a QFT negative South African
population, the high prevalence ofM.tb infection in adults makes
this challenging, and the QFT+ individuals are healthy from
a clinical standpoint. The differences in IFNα concentrations
observed between the healthy European and LTBI controls are
interesting, and may be due to either environmental or genetic
differences, which will require further study in well-defined
population cohorts.
Furthermore, identification of the origin and source of type
I interferon will require additional studies in relevant animal
models, where access to infected tissue is possible. Additionally
given the transient nature of type I IFN protein secretion,
immune stimulation may be required to reveal such potential
differences. This will help to clarify the controversial role of type I
interferons in TB disease andmay help in the future development
of new diagnostic tools, vaccines and treatments.
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